

## Notes to editors

### About ONTARGET®

The ONTARGET® Trial Programme consists of two randomised, double-blind, multicentre international trials: the principle trial, ONTARGET® which reports its results today, and a parallel trial TRANSCEND® (Telmisartan Randomized Assessment Study in ACE-I INTolerant subjects with cardiovascular Disease), which is planned to be reported later in the year.<sup>3</sup>

The treatment arms for the ONTARGET® Trial were telmisartan 80mg, ramipril 10mg, and combination therapy with telmisartan 80mg and ramipril 10mg. In the TRANSCEND® trial the treatment arms are telmisartan 80mg or placebo – both on top of standard blood pressure care, not including an ACE or another ARB.<sup>3</sup>

Patients enrolled in The ONTARGET® Trial Programme were aged ≥ 55 years, had a history of coronary artery disease, stroke or recent (> 7 days, < 1 year) transient ischaemic attack, peripheral vascular disease, or diabetes mellitus with target-organ damage such as microalbuminuria, ankle-brachial index < 0.8, or left ventricular hypertrophy.<sup>3</sup>

The ONTARGET® Trial had a four-fold composite endpoint:

- cardiovascular death,
- myocardial infarction,
- stroke, and
- hospitalisation for heart failure.

Patients intolerant to ACEs were not eligible for the ONTARGET® study. Intolerance to ACE was a requirement for enrolment into TRANSCEND®.

### About telmisartan (MICARDIS®/Kinzal®/Pritor®)

Telmisartan is a member of the angiotensin II receptor blocker (ARB) class and approved for the treatment of mild to moderate hypertension. It is being investigated in the most ambitious and far-reaching research programme ever conducted with an ARB. In the ongoing clinical trial programmes ONTARGET®, PROTECTION® and PProFESS®, over 58,000 patients have been enrolled to investigate the cardiovascular protective effects of telmisartan.

Telmisartan was discovered and developed by Boehringer Ingelheim. Under the trademarks MICARDIS® and MICARDISPLUS® (combination with hydrochlorothiazide) the company markets telmisartan in 84 countries around the world, including the USA, Japan and European countries. Telmisartan is marketed in

cooperation with Astellas Pharma Inc. in Japan, Bayer HealthCare in Europe and GlaxoSmithKline in selected markets.

Astellas Pharma Inc. co-promotes telmisartan under the trademark MICARDIS<sup>®</sup>, Bayer HealthCare promotes telmisartan under the brand names Kinzalmono<sup>®</sup>, Kinzalkomb<sup>®</sup> (combination with hydrochlorothiazide), and Pritor<sup>®</sup> and PritorPlus<sup>®</sup> in markets across Europe. Pritor<sup>®</sup> and PritorPlus<sup>®</sup> is also marketed by GlaxoSmithKline in selected markets.

### **About Boehringer Ingelheim**

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2006, Boehringer Ingelheim posted net sales of 10.6 billion euro while spending one fifth of net sales in its largest business segment, Prescription Medicines, on research and development. 2007 business figures will be available from 8 April 2008 onwards.

For more information please visit [www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)

Please note MICARDIS<sup>®</sup> is registered for the indication mild-moderate hypertension only. While presenting the scientific results of the ONTARGET<sup>®</sup> study, Boehringer Ingelheim does not recommend the use of MICARDIS<sup>®</sup> in patients that do not fulfill the criteria of the prescribing information.

### **References**

1. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. Published online 31 Mar 2008.
2. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. *N Engl J Med* 2000; **342**:145-53.
3. The ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) trials *Am Heart J* 2004; **148**(1):52-61.
4. Bakris G, *et al*. Influence of glycemic control on proteinuria in patients with type 2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial.

67th Sci Sess of the American Diabetes Association (ADA), Chicago, 22 - 26 Jun 2007 (Poster) 2007.

5. Williams B, *et al.* The prospective, randomised investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMAI). *J Hypertens* 2006; **24**:193-200.
6. Lacourcière Y, *et al.* A multicenter, 14-weeks study of telmisartan and ramipril in patients with mild to moderate hypertension using ambulatory blood pressure monitoring. *Am J Hypertens* 2006; **19**:104-12
7. World Health Organization, Fact Sheet 317: Cardiovascular Diseases February 2007. <http://www.who.int/mediacentre/factsheets/fs317/en/index.html> (Accessed March 2008)
8. Murray CJL, Lopez AD. eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge; Harvard University Press 2001.
9. Primary Prevention of Ischemic Stroke. A Guideline From the American Heart Association/American Stroke Association Stroke Council. *Stroke* 2006; **37**:1583-1633.